Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

NCT03623568 is registered in ClinicalTrials.gov with Raymond T. Chung, MD as lead sponsor.

NCT NCT03623568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03623568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant
Lead sponsor
Raymond T. Chung, MD
Phase
Phase 4
Overall status
Withdrawn
Start date
February 15, 2019
Completion date
April 15, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, kidney diseases, kidney failure